What is the expected trickle-down effect of this for GSK Colombia?
Reilly: We are growing. Our headcount is on the increase because we adapted shortly after the merger. We have gone through various phases of restructuring since 2002. At the moment the structure we have is in line with market needs and now we are in fact adding on extra specialized field force to manage Oncology. With the purchase of Stiefel we are taking in and increasing our sales force also. Although we constantly reassess the adequacy of our headcount as compared to our growth target and market benchmarking, needs and conditions, currently countries in emerging markets where growth potential is seen, such as Colombia, are investing. While you referenced earlier Colombia to be a stable, reliable “brick,” with its steady growth potential do you foresee it joining the elite class of acronym-ed BRICs? Reilly: No, it does not have the population for that. When you look at the BRICs the population of those countries is what makes them the BRICs. Colombia is the third business market in L
